Evaluation of fetomaternal results in preeclampsia patients

Yıl 2019, Cilt: 4 Sayı: 2, 44 - 52, 25.12.2019

Abdulmecit Öktem Murat Alan Yasemin Alan Mehmet Özeren

Öz

Abstract:

OBJECTIVE: The aim of this study
is to evaluate retrospectively the fetomaternal results of the patients with
preeclampsia and to contribute to the treatment and management protocols.

METHODS: This study was performed
retrospectively in Tepecik Training and Research Hospital which is the most
referral hospital in its region between January 2013 and December 2014.
Computer-based patient data records were reviewed in detail for the study.  The obstetric records of all patients with
preeclampsia and eclampsia diagnostic code were examined and the cases were
divided into two groups as severe preeclampsia (SP) and non-severe preeclampsia
(NSP). Both groups were compared in terms of clinical features, serum markers
maternal and fetal complications.

FINDINGS: In our center, a total
of 128; 32 (25%) NSP and 96 SP (75%) cases were included in the study. There
was no statistically significant difference in age, BMI, gravida and parity in
both groups. In SP group, arterial blood pressure measurements, in Aspartat
aminotransferaz  (AST), alanin
aminotransferaz (ALT) and NSP group thrombocyte average were significantly
higher. There was no statistically significant difference between the two
groups for other serum parameters. Although preterm labor was statistically
significant in SP group, there was no statistically significant difference
between maternal and fetal complications in both groups.

RESULT:

In order to prevent this group
from these kinds of diseases whose etiology is not known exactly which is not
possible to be determined beforehand, the patient people must have a health check
without being pregnant.   Especially,
those with risk factors, antenatal pregnancy follow-up period perıodical
controls should be made regularly, when the disease is detected, delivery, if
possible, in tertiary centers with maternal and neonatal intensive care
conditions, will positively affect both perinatal and maternal mortality and
morbidity.

Key words: preeclampsia,
eclampsia, maternal and fetal outcomes

Anahtar Kelimeler

preeclampsia, eclampsia, fetal outcomes

Kaynakça

• References:1.Preeclampsia: an update. Lambert G, Brichant JF, Hartstein G, Bonhomme V, Dewandre PY. Acta Anaesthesiol Belg. 2014;65(4):137-49.2.Preeclampsia - Current Management and Future Approach. Dymara-Konopka W, Laskowska M, Oleszczuk J. Curr Pharm Biotechnol. 2018 Sep 25. doi: 10.2174/1389201019666180925120109. 3.Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. Yücesoy G, Ozkan S, Bodur H, Tan T, Calişkan E, Vural B, Corakçi A.Arch Gynecol Obstet. 2005 Nov;273(1):43-9. .4. Diagnosis and management of gestational hypertension and preeclampsia. Sibai BM. Obstet Gynecol. 2003 Jul;102(1):181-92.5. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002 Jan;99(1):159-67.6. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22..7. Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome. Kongwattanakul K, Saksiriwuttho P, Chaiyarach S, Thepsuthammarat K. Int J Womens Health. 2018 Jul 17;10:371-377. doi: 10.2147/IJWH.S1685698. Hypertension and pregnancy. Deak TM, Moskovitz JB. Emerg Med Clin North Am. 2012 Nov;30(4):903-17. doi: 10.1016/j.emc.2012.08.006.9. Hypertensive disorders of pregnancy. Leeman L, Fontaine P. Am Fam Physician. 2008 Jul 1;78(1):93-100.10.Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. Jim B, Karumanchi SA. Semin Nephrol. 2017 Jul;37(4):386-397. doi: 10.1016/j.semnephrol.2017.05.011.11.Hypertensive disease of pregnancy and maternal mortality. Lo JO, Mission JF, Caughey AB. Curr Opin Obstet Gynecol. 2013 Apr;25(2):124-32. doi: 10.1097/GCO.12. Hypertensive Emergencies in Pregnancy. Olson-Chen C, Seligman NS. Crit Care Clin. 2016 Jan;32(1):29-41. doi: 10.1016/j.ccc.2015.08.00613. Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. Houlihan DD, Dennedy MC, Ravikumar N, Morrison JJ. J Perinat Med. 2004;32(4):315-9.14. Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM. Am J Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Obstet Gynecol. 1999 Jan;180(1 Pt 1):221-515. Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG:The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification.Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1373-84.16.Selahattin Kumru, Mehmet fiimflek, Bilgin Güratefl, Ekrem Sapmaz, Zeynep Özcan,Mehmet Nalbant, Denizmen Aygün: Comparison of Maternal and Perinatal Outcomes of HELLP Syndrome and Severe Preeclampsia Cases. Perinatal Journal • Vol: 13, Issue: 1/March 200517. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163: 1049–55.18. Bánhidy F, Acs N, Puhó EH, Czeizel AE. Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertens Res. 2011;34(2):257–63. doi: 10.1038/hr.2010.227.19. Are hypertensive disorders in pregnancy associated with congenital malformations in offspring? Evidence from the WHO Multicountry cross sectional survey on maternal and newborn health.S. Bellizzi, M. M. Ali, E. Abalos, A. P. Betran, J. Kapila, C. Pileggi-Castro, J. P. Vogel, and M. Merialdi. BMC Pregnancy Childbirth. 2016; 16: 198.20.Lopez-Llera M. Main clinical types and subtypes of eclampsia. Am J Obstet Gynecol 1992; 166: 4–9.21.Gul A, Cebeci A, Aslan H, Polat I, Ozdemir A, Ceylan Y. Perinatal Outcomes in Severe Preeclampsia-Eclampsia with and without HELLP Syndrome. Gynecol Obstet Invest 2005; 59: 113-8.22. Murphy DJ, Stirrat GM. Mortality and morbidity associated with early-onset preeclampsia. Hypertens Pregnancy 19(2).221-31, 200032-Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM. Am J Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Obstet Gynecol. 1999 Jan;180(1 Pt 1):221-5 23. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM.HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: onset at < or=28.0 weeks' gestation. Am J Obstet Gynecol 2000(a); 183:1475-924. The complication and mode of delivery in Chinese women with severe preeclampsia: a retrospective study.Zhang Y, Li W, Xiao J, Chen S. Hypertens Pregnancy. 2014 Aug;33(3):283-90. doi: 10.3109/10641955.2013.874440. 25. Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. Journal of pregnancy. 2011;2011:214365.26.Impact of fetal growth on pregnancy outcomes in women with severe preeclampsia.Carter EB, Conner SN, Cahill AG, Rampersad R, Macones GA, Tuuli MG.27. Evaluation of Maternal and Perinatal Findings in Mild and Severe Preeclampsia Cases. Cuma TAŞIN, Yunus YILDIZ, Bekir Serdar ÜNLÜ, Hasan ENERGİN, Nesrin CEYLAN Kocatepe Medical Journal 2014;15(1):7-12 28.Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000; 182: 307–12.